The efficacy of human chorionic gonadotropin in retractile testis.
OBJECTIVE
To evaluate the efficacy of hCG therapy on retractile testis in various testicular locations and age groups.


METHODS
This study comprised 123 boys whose diagnosis were retractile testis with scrotal base, high scrotal and superficial inguinal localizations with an average age of 4,2 (1-8) years.


METHODS
123 boys with retractile testes were given a total dose of 9000 hCG and its effect on scrotal base, high scrotal and superficial inguinal located testes were evaluated after 2 weeks and 6 months of completing hCG course. The patients were evaluated in four age groups such as less than 2 years of age, between 2-4, 4-6 years and more than 6 years of age and the response rates were also noted in these age groups.


RESULTS
In unilateral cases, the response in base, high scrotal and superficial inguinal levels were found as 100%, 83,3%, 72,7% respectively where as these rates were found as 100%, 92,6%, 76,3% respectively in bilateral cases after 2 weeks of hCG therapy. The response rates in less than 2 year old group, 2-4, 4-6 and more than 6 years group were found as 0%, 80%, 78,7%, 100% respectively in unilateral cases and 33,3%, 90%, 86,9% and 83,3% respectively in bilateral cases. After 6 months, reascend was observed in 12,4% in unilateral group and 6,7% in bilateral group.


RESULTS
72,7-100% of retractile testes respond to hCG administration with the highest response in the age of more than six year group.


CONCLUSIONS
High response rates observed in retractile testes after hCG therapy in more than 2 years old age group indicate that hCG must be given as a primary treatment in retractile testes and orchiopexy for the failures. Also patients must be followed up closely for reascend cases.
Metin
Ahmet
A
Urology Clinics of Abant, Izzet Baysal Medical Faculty, Bolu, Turkey. drmetin@anet.net.tr
Kayigil
Onder
O
Ahmed
S Iftekhar
SI
D000375:Aging / Q000502:physiology; D002675:Child, Preschool; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003456:Cryptorchidism / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D008297:Male; D012611:Scrotum / Q000473:pathology
D006063:Chorionic Gonadotropin